Despite early signs of on-target pharmacological activity, Septerna has decided to focus on advancing next-generation PTH1R agonists with distinct chemical structures. Jeffrey Finer, CEO and co ...

The G protein-coupled receptor (GPCR)-focused company had been testing SEP-786, an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R), in a phase 1 trial of healthy volunteers.

SEP-786 is an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) being developed for the treatment of hypoparathyroidism. Septerna’s decision follows the observation of two ...

SEP-786 is an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) being developed for the treatment of hypoparathyroidism. Septerna’s decision follows the observation of ...

Trial decision follows unanticipated events of elevated unconjugated bilirubin levels Company advancing multiple next-generation PTH1R agonists with distinct and unrelated chemical structures ...